What is claimed is :

1. A sustained release formulation for oral administration of an HMG-CoA reductase inhibitor comprising:

a solid dispersant including the HMG-CoA reductase inhibitor, a solubilizing agent, and a stabilizing agent;

a sustained release composite carrier; and

a gel hydration accelerator.

2. The sustained release formulation of claim 1, wherein the solubilizing agent is 0.05 to 20 weight part; the stabilizing agent is 0.01 to 0.1 weight part; the sustained release composite carrier is 3 to 30 weight part; and the gel hydration accelerator is 0.1 to 5 weight part based on 1 weight part of the HMG-CoA reductase inhibitor.

3. The sustained release formulation of claim 1, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, pravastatin, lactone of pravastatin, velostatin, simvastatin, rivastatin, fluvastatin, atorvastatin, cerivastatin and a pharmaceutically acceptable salt thereof.

4. The sustained release formulation of claim 3, wherein the HMG-CoA reductase inhibitor is simvastatin or a pharmaceutically acceptable salt thereof.

5. The sustained release formulation of claim 1, wherein the solubilizing agent is selected from the group consisting of d-α-tocopheryl polyethylene glycol 1000 succinate, polyoxyethylene stearic acid ester, polyethylene glycol and polyoxypropylene-polyoxypropylene block copolymer.

6. The sustained release formulation of claim 1, wherein the stabilizing agent is selected from the group consisting of butylated hydroxy toluene, butylated hydroxy anisol, erythorbic acid and ascorbic acid.

7. The sustained release formulation of claim 1, wherein the solid dispersant further includes a pharmaceutically acceptable solubilizing carrier.

8. The sustained release formulation of claim 1, wherein the sustained release composite carrier is a mixture of sodium alginate and xanthan gum.

9. The sustained release formulation of claim 8, wherein the sustained release composite carrier includes 0.1 to 10 weight part of the xanthan gum based on 1 weight part of the sodium alginate.

10. The sustained release formulation of claim 8, wherein the sustained release composite carrier further includes locust bean gum.

11. The sustained release formulation of claim 10, wherein the sustained release composite carrier includes 0.1 to 5 weight part of the locust bean gum based on 1 weight part of the sodium alginate.

12. The sustained release formulation of claim 1, wherein the gel hydration accelerator is a mixture of propylene glycol ester alginate and hydroxypropyl methyl cellulose.

13. The sustained release formulation of claim 12, wherein the gel hydration accelerator includes 0.05 to 20 weight part of the propylene glycol ester alginate based on 1 weight part of the hydroxypropyl methyl cellulose.

14. The sustained release formulation of claim 13, wherein the hydroxypropyl methyl cellulose has a viscosity ranging from 4,000 to 100,000 cps.

15. The sustained release formulation of claim 1, further comprising a pharmaceutically acceptable additive selected from the group consisting of a binder, a lubricating agent, a sweetening agent and an excipient.

16. A method for preparing the sustained release formulation of claim 1, comprising the steps of:

(1) mixing the HMG-CoA reductase inhibitor, the solubilizing agent, and the stabilizing agent in a solvent to obtain the solid dispersant;

(2) homogeneously mixing the sustained release composite carrier and the gel hydration accelerator with the solid dispersant to form a first mixture;

(3) adding a pharmaceutically acceptable additive to the first mixture to form a second mixture; and

(4) dry-mixing and formulating the second mixture into a solid formulation.

17. The method of claim 16, wherein the solid dispersant is prepared by a method selected from the group consisting of a spray-drying method, a solvent evaporation method, a pulverizing wet method, a melting method and a freeze-drying method.